SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...

Pluri, Inc. ('Pluri”, the 'Company”, 'we” or 'us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its ...

Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...

Cellular immunotherapy—for example, Chimeric Antigen Receptor (CAR)-T cell therapy—has shown great efficacy in treating various hematologic malignancies. CAR-T therapy has undergone notable changes, ...

Editor’s note: BioPharma Dive, as part of Emerging Biotech Weekly, is taking a closer look at competitive areas of startup activity. We aim to give an overview of the companies developing a new ...

Achieving the manufacturing throughput necessary to satisfy expected patient demand is dependent on several factors, including decreasing reliance on large, expensive manufacturing facilities; ...

DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...

CAPEX investment for setting up the PERC production is higher in the case of a MLD setup. Image: Fraunhofer ISE A solar cell manufacturing plant can reduce water consumption by up to 79% with existing ...